Tag Archive for: Immunity

Asgard Therapeutics announces publication in Immunity demonstrating induction of cancer-fighting tertiary lymphoid structures across seven tumor types – and will present new AT-108 biomarker data at SITC 2026

Study in Immunity highlights Asgard’s ability to generate potent immunogenic tertiary lymphoid structures (imgTLSs) solely by reprogramming tumor cells into antigen-presenting conventional type 1 dendritic cells (cDC1s) directly within tumors. imgTLS formation seen across seven different tumor types from inflamed to non-T-cell inflamed and in immunosuppressed tumor microenvironments, demonstrating tumor-agnostic activity. Tumor-to-dendritic cell reprogramming led […]

© Optimum Strategic Communications.